David Ian Bell is the Chief Innovation Officer for Grifols S.A. Additionally, he is the President and Chief Executive Officer of Grifols Innovation and New Technology Limited (GIANT). He also serves as General Counsel with responsibility for, among other things, mergers and acquisitions and new business development. Mr. Bell serves on Grifols Corporate, Strategy, Bioscience, Diagnostic and Hospital Management/Executive Committees and is on the Board of Directors of numerous Grifols’ portfolio companies. Mr. Bell is currently the Chairman of the Plasma Protein Therapeutics Association. Prior to joining Grifols in 2003, Mr. Bell served as General Counsel and Vice President of Alpha Therapeutic Corporation following more than 20 years as a corporate lawyer specializing in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Irvine focusing on Psychobiology (Neuroscience), Southwestern University School of Law and a postgraduate program at Harvard Law School.